Radnostix Inc. Reports 27% Revenue Decline and Increased Net Loss in Q2 2026

Radnostix Inc. reported a significant decline in financial performance for the second quarter of 2026, with total revenue of $2.67 million, down 27% from $3.66 million in the same period last year. For the first half of 2026, revenue also decreased by 27% to $5.05 million compared to $6.89 million in the first half of 2025. The company attributed this decline primarily to lost sales in its Theranostics Products segment, which experienced two voluntary product recalls earlier in the year, as well as decreased sales in the Cobalt Products segment due to operational shutdowns for maintenance.

The company's net loss for the second quarter was $882,000, a substantial increase from a loss of $161,000 in the same quarter of 2025. For the first half of 2026, the net loss widened to $2.23 million compared to a loss of $273,000 in the prior year. This increase in losses was driven by the aforementioned sales declines and increased operating expenses, particularly in salaries and research and development, which rose due to stock-based compensation and heightened development activities in the Medical Device segment.

In terms of operational metrics, Radnostix's cash and cash equivalents decreased to $1.20 million as of June 30, 2026, down from $1.70 million at the end of 2025. The company reported net cash used in operating activities of $686,000 for the first half of 2026, contrasting with net cash provided of $310,000 in the same period of 2025. Inventory levels also fell to $644,519 from $875,449, reflecting the company's efforts to manage costs amid declining sales.

Strategically, Radnostix has been active in expanding its product offerings and capabilities. The company completed the acquisition of assets from Lucerno Dynamics, which includes technology related to radiation detection and medical devices, and is working on the development of its EasyFill Iodine Encapsulation System, expected to launch in early 2027. Additionally, the company has been focusing on its joint ventures, including a partnership with Alpha Nuclide Inc. for the distribution of its Theranostics Products in China.

Looking ahead, Radnostix expects that its current cash balance, along with potential equity or debt financing, will be sufficient to fund operations for the next twelve months. However, the company acknowledged that future liquidity and capital funding will depend on various factors, including market conditions and the success of its strategic initiatives. The management remains cautious, emphasizing the need for careful monitoring of operational performance and market dynamics as they navigate through these challenges.